Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.50 Contact Hours.

Acknowledgment of Commercial Support

This educational activity is supported by educational grants from AbbVie Inc.; AstraZeneca; Genmab US, Inc.; Incyte Corporation; Oncopeptides, Inc.; Pfizer Inc.; and Sanofi Genzyme.

Medical Crossfire®: Perfecting the Diagnosis and Treatment of EGPA: Patient Perspectives and Expert Insight

Release Date: August 18, 2020
Expiration Date: August 18, 2021

Activity Overview

This online educational activity is designed to provide expert interpretation of new and emerging data on the treatment of eosinophilic granulomatosis with polyangiitis (EGPA) and important aspects of clinical presentation. The nuances of diagnosis, current and emerging treatments, and coordination of a multidisciplinary care team is presented in a multimedia format, including a series of video interviews with expert thought leaders integrated into text-based elements.

This activity is supported by an educational grant from GlaxoSmithKline.

This activity is supported by an educational grant from GlaxoSmithKline.

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.

Target Audience

This educational program is directed toward all pulmonologists, primary care physicians, rheumatologists, nurse practitioners, physician assistants, and other health care professionals who treat EGPA.

Learning Objectives

Upon successful completion of this educational activity, you should be better prepared to:

  • Evaluate recommendations for early assessment and diagnosis for patients with EGPA
  • Discuss relevant patient insights and strategies to improve the collaborative care approach
  • Assess disease progression to properly screen and diagnose EGPA and develop an individualized management plan

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER® has identified and resolved all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.


Michael E. Wechsler, MD, MMSc
Michael E. Wechsler, MD, MMSc
Professor of Medicine
Director, The Cohen Family Asthma Institute
Division of Pulmonary, Critical Care & Sleep Medicine
National Jewish Health
Denver, CO

Disclosures: Grant Research Support: AstraZeneca, Regeneron, Sanofi, Teva; Consultant: AstraZeneca, Equillium, Genentech, Sanofi Genzyme, GlaxoSmithKline,Novartis, Regeneron, resTORbio, Sanofi

Praveen Akuthota, MD
Praveen Akuthota, MD
Associate Clinical Professor of Medicine
University of California, San Diego
La Jolla, CA

Disclosures:Grant Research Support: AstraZeneca, GlaxoSmithKline; Consultant:AstraZeneca, GlaxoSmithKline

Disclosures: Grant Research Support: Exelixis, Janssen Pharmaceuticals, Seattle Genetics; Consultant: Astellas Pharma, Eisai, Genentech, Merck & Co, Novartis, Orion Corporation, Pfizer, Seattle Genetics.

Anisha Dua, MD, MPH
Anisha Dua, MD, MPH
Associate Professor of Medicine (Rheumatology)
Rheumatology Fellowship Program Director
Director, Vasculitis Center
Northwestern University Feinberg School of Medicine
Chicago, IL

Disclosures:Consultant: ChemoCentryx, GlaxoSmithKline

Rula A. Hajj-Ali, MD, FACP
Rula A. Hajj-Ali, MD, FACP
Professor of MedicineAssociate Director
Center for Vasculitis Care and Research
Cleveland Clinic
Cleveland, OH

Disclosures:Consultant: Astellas Pharma, AstraZeneca, Bayer, Foundry, Janssen Pharmaceuticals, Sanofi, Sema4, TeneoBio

The staff of Physicians' Education Resource®, LLC (PER®) have no relevant financial relationships with commercial interests to disclose.


Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By